Mark J. Gergen has been appointed senior vice president and chief operating officer at Halozyme Therapeutics, Inc. He reports to Dr. Helen Torley, president and chief executive officer.

Mr. Gergen will be responsible for corporate development, including the management of Halozyme's ENHANZE platform collaborations and overseeing the global product teams responsible for planning development and commercialization of its oncology pipeline, including clinical operations and clinical collaborations.

"Mark brings a wealth of business development and operational experience that will be essential as we execute our plan to accelerate growth of the ENHANZE platform and develop and commercialize multiple oncology drugs," said Dr. Torley. "With more than 20 years of healthcare and biotech experience, he will be a strong addition to our management team as we execute our growth strategy."
Mr. Gergen joins the company from Mirati Therapeutics, an oncology biotech, where he was executive vice president and chief operating officer responsible for the strategy, corporate development, finance, investor relations, human resources, information technology and legal functions. He executed multiple successful partnerships, collaborations and licensing agreements.